reports
Kinder Morgan Inc: 1 director
A director at Kinder Morgan Inc sold 50,000 shares at 19.750USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)...
Lifecore Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHASKA, Minn., May 22, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization, today announced that Lifecore has granted a restricted stock unit (“RSU”) award with respect to 525,000 shares of its common stock and a performance stock unit (“PSU”) award for up to 1,500,000 shares of its common stock to Paul Josephs, Lifecore’s newly hired President and Chief Executive Officer. The RSU award and PSU award w...
Lifecore Biomedical Completes Incremental Liquidity Initiatives
Lifecore Biomedical Completes Incremental Liquidity Initiatives Recent Initiatives Provide Approximately $8 Million of Non-Dilutive, Incremental Liquidity through Various Amendments with Lenders CHASKA, Minn., May 16, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), announced certain incremental liquidity measures and housekeeping matters related to divested businesses through a series of 8-K filings over the past week. James G. Hall, President and Chief Exec...
- Valens Research
Valens Equity Weekly Insights - 2024 05 07
Kinder Morgan (KMI) is the biggest natural gas pipeline company in the U.S. Its dominant position has allowed it to have stable profitability the last several years even when natural gas prices and volumes were low. Now that the natural gas market is improving thanks to better compression technology and higher demand from Europe, Kinder Morgan can start making more money on its contracts. Uniform Accounting highlights that the market is not pricing in a profitability inflection for the company,...
Allison Transmission Holdings Inc: 1 director
A director at Allison Transmission Holdings Inc sold 7,700 shares at 75.696USD and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last ...
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delaye...
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report CHASKA, Minn., April 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that, on April 15, 2024, the Company received a notification letter (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of the Company’s delay in filing its Quarterly Report on Form 10-Q for the fiscal quarter ended February 25, 2024 (the “Q3 Form 10-Q”) and its continued delay in filing its Quarterly Rep...
Kinder Morgan Reports First Quarter 2024 Financial Results
HOUSTON--(BUSINESS WIRE)-- Kinder Morgan, Inc.’s (NYSE: KMI) board of directors today approved a cash dividend of $0.2875 per share for the first quarter ($1.15 annualized), payable on May 15, 2024, to stockholders of record as of the close of business on April 30, 2024. This dividend is a 2% increase over the first quarter of 2023. The company is reporting: First quarter earnings per share (EPS) of $0.33 and distributable cash flow (DCF) per share of $0.64, up 10% and 5%, respectively, compared to the first quarter of 2023. Net income attributable to KMI of $746 million, compared to $...
Kinder Morgan Announces First Quarter ‘24 Earnings Webcast
HOUSTON--(BUSINESS WIRE)-- Kinder Morgan, Inc. (NYSE: KMI) today announced it will release first quarter 2024 earnings results on Wednesday, April 17, 2024 after market close and will hold a live webcast and conference call. What: Kinder Morgan First Quarter ‘24 Earnings Results Webcast When: April 17, 2024, at 3:30 p.m. CT, 4:30 p.m. ET Where: How: Live over the Internet by logging on to the web at the above address, or by phone (listen-only) by dialing 1-517-308-9431 and entering the passcode 8305461. If you are unable to listen during the live webcast, the call will be archived a...
Kinder Morgan Announces Amy W. Chronis as Nominee for Election to Boar...
HOUSTON--(BUSINESS WIRE)-- Kinder Morgan, Inc. (NYSE: KMI) today announced that its board of directors has nominated Amy W. Chronis to stand for election as a director at its annual meeting of stockholders on May 8, 2024. Ms. Chronis is a Senior Partner with Deloitte and is scheduled to retire from Deloitte as of June 1, 2024. She served as Deloitte’s Vice Chair and US Energy & Chemicals Industry Leader from January 2021 to January 2024 and as the Managing Partner of Deloitte’s Houston practice from February 2018 to January 2024. She joined Deloitte as a Partner in June 2002. In addition t...
Lifecore Biomedical Provides Business Update Outlining Fiscal 2024 Out...
Lifecore Biomedical Provides Business Update Outlining Fiscal 2024 Outlook and Year-to-date Progress Year-to-date Results Consistent with Prior Expectations; Experiencing Fiscal Second Half Lift Provides Fiscal 2024 Full Year Guidance Commercial Momentum Continues within Development Portfolio Capacity Expansion Projects Progressing CHASKA, Minn., April 01, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today provided a business update, including certain se...
Lifecore Biomedical Announces Pending Change of Auditor and Provides E...
Lifecore Biomedical Announces Pending Change of Auditor and Provides Expectation for Business Update CHASKA, Minn., March 26, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), announced today that Ernst & Young LLP, the Company’s independent registered public accounting firm for the fiscal year ended May 28, 2023, determined that it declined to stand for reappointment as the Company’s independent registered public accounting firm for the Company’s fiscal year en...
Lifecore Biomedical Concludes Strategic Evaluation Process, Announces ...
Lifecore Biomedical Concludes Strategic Evaluation Process, Announces Management Succession and Board Changes Appoints Paul Josephs, an executive with 25 years of CDMO experience as CEO, to succeed current CEO James Hall following his retirement Announces changes to its Board of Directors, appoints new Board Chair CHASKA, Minn., March 20, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that its Board of Directors unanimously approved the concl...
Lifecore Biomedical Completes Restatements and Files Form 10-K for Fis...
Lifecore Biomedical Completes Restatements and Files Form 10-K for Fiscal Year 2023 Efforts now aligned toward the completion of its First Quarter Fiscal 2024 Report on Form 10-Q CHASKA, Minn., March 20, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), announced today that it has filed its Annual Report on Form 10-K for the fiscal year ended May 28, 2023 (“FY23”) with the United States Securities and Exchange Commission (the “SEC”). Form 10-K Filing and Resta...
Lifecore Biomedical, Inc. Announces Receipt of Nasdaq Notice of Delist...
Lifecore Biomedical, Inc. Announces Receipt of Nasdaq Notice of Delisting and Intention to Appeal Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company’s Securities CHASKA, Minn., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that on February 13, 2024 it received a Staff Delisting Determination (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq has initiated which could result in the delisting...
Kinder Morgan to Hold 2024 Investor Day
HOUSTON--(BUSINESS WIRE)-- Representatives of Kinder Morgan, Inc. (KMI) intend to make presentations in Houston, Texas on January 24, 2024 at the Kinder Morgan 2024 Investor Day regarding the company’s strategy and long-term outlook, the results for fiscal year 2023 and the financial budget for 2024. Interested parties will be able to view the materials to be presented at the event by visiting KMI’s website at: . The presentations will also be accessible by audio webcast (both live and on-demand) on KMI’s website at the same web address. Live presentations are scheduled to begin at 9 a.m. CT...
Kinder Morgan Reports Fourth Quarter 2023 Financial Results
HOUSTON--(BUSINESS WIRE)-- Kinder Morgan, Inc.’s (NYSE: KMI) board of directors today approved a cash dividend of $0.2825 per share for the fourth quarter ($1.13 annualized), payable on February 15, 2024, to stockholders of record as of the close of business on January 31, 2024. This dividend is a 2% increase over the fourth quarter of 2022. The company is reporting: Fourth quarter earnings per share (EPS) of $0.27 and distributable cash flow (DCF) per share of $0.52, down 10% and 4%, respectively, compared to the fourth quarter of 2022. Net income attributable to KMI of $594 million, ...
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delaye...
Lifecore Biomedical, Inc. Receives Notice from Nasdaq Regarding Delayed Quarterly Report CHASKA, Minn., Jan. 12, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (the “Company”) announced today that it received a notice (“Notice”) on January 10, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) because the Company failed to timely file its Interim Report on Form 10-Q for the period ended November 29, 2023 (the “Q2 Form 10-Q”), and beca...
Kinder Morgan Announces Fourth Quarter ‘23 Earnings Webcast
HOUSTON--(BUSINESS WIRE)-- Kinder Morgan, Inc. (NYSE: KMI) today announced it will release fourth quarter 2023 earnings results on Wednesday, January 17, 2024 after market close and will hold a live webcast and conference call. What: Kinder Morgan Fourth Quarter ‘23 Earnings Results Webcast When: January 17, 2024, at 3:30 p.m. CT, 4:30 p.m. ET Where: How: Live over the Internet by logging on to the web at the above address, or by phone (listen-only) by dialing 1-210-234-0023 and entering the passcode 3265653. If you are unable to listen during the live webcast, the call will be arch...
Lifecore Biomedical Expands Relationship with Existing Long-Term Custo...
Lifecore Biomedical Expands Relationship with Existing Long-Term Customer Through a Series of Commercial Arrangements Lifecore enters into commercial agreements with Alcon that include new 8-year commercial manufacturing arrangements Lifecore receives amendment and waiver for its term debt facility with Alcon and BMO CHASKA, Minn., Jan. 05, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore" or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that it has finalized a series of updated commercial arr...
- Dave Nicoski
- Ross LaDuke
ANTM ANTHEM INC.
TSN TYSON FOODS INC. CLASS A
RYAM RAYONIER ADVANCED MATERIALS INC
RY. ROYAL BANK OF CANADA
MRK MERCK & CO. INC.
LAZ LAZARD LTD CLASS A
KHC KRAFT HEINZ COMPANY
K KELLOGG COMPANY
GIS GENERAL MILLS INC.
GILD GILEAD SCIENCES INC.
FIBK FIRST INTERSTATE BANCSYSTEM INC. CLASS A
CVS CVS HEALTH CORPORATION
CPB CAMPBELL SOUP COMPANY
CNC CENTENE CORPORATION
CF CF INDUSTRIES HOLDINGS INC.
CAG CONAGRA BRANDS INC.
BGS B&G FOODS INC.
ARWR ARROWHEAD PHARMACEUTICALS INC.
ABUS ARBUTUS BIOPHARMA CORP.
VIRT VIRTU FINANCIAL INC. CLASS A
FDP FRESH DEL MONTE PRODUCE INC.
CENX CENTURY ALUMINUM COMPANY
KMI KINDER MORGAN INC CLASS P
KO COCA-COLA COMPANY
LMT LOCKHEED MARTIN CORPORATION
SJM J.M. SMUCKER COMPANY
ABBV ABBVIE INC.
MRNA MODERNA INC.
VTRS VIATRIS INC.
RLAY RELAY THERAPEUTICS
RNA AVIDITY BIOSCIENCES
DOLE DOLE PLC
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.